Business Context and Reporting Period
Company: Corbus Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 5, 2015
Purpose: Correction of the form of the "Investor Warrant" previously filed as Exhibit 4.3 to the Company's Registration Statement on Form S-1 (filed September 3, 2014).
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the correction of a legal instrument related to a prior private placement.
Material Changes and Warrant Details
The filing clarifies the terms of Investor Warrants issued in connection with a 2014 private placement. Key terms include:
- Shares Underlying Warrants: Aggregate of 10,260,000 shares of Common Stock.
- Exercise Price: $1.00 per share.
- Exercise Period: Currently exercisable for a period of five years from the date of issuance.
- Redemption Rights: The Company may redeem the warrants if the volume-weighted average price of the Common Stock is equal to or greater than $2.50 per share for twenty (20) consecutive trading days, provided a registration statement covering the resale of underlying shares is effective.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the specific terms of the warrant redemption.
Investor Verification Checklist
- Verify the effective status of the Registration Statement covering the resale of shares underlying the Investor Warrants to confirm redemption eligibility.
- Confirm the current volume-weighted average price of the Common Stock relative to the $2.50 redemption threshold.
- Review the original Form S-1 (File No. 333-198563) to compare the corrected warrant form against the initial filing.